Carbetocin

Carbetocin (1-deamino-1-monocarba-(2-O-methyltyrosine)-oxytocin; CAS 37025-55-1; molecular formula C45H69N11O12S; molecular weight 988.16) is a synthetic long-acting analog of the neurohypophysial peptide oxytocin, developed for the prevention of uterine atony and postpartum hemorrhage following cesarean and vaginal delivery. The compound incorporates two critical structural modifications relative to native oxytocin: replacement of the disulfide bridge with a thioether (monocarba) linkage that confers resistance to disulfide reductases, and deamination of the N-terminal cysteine residue that eliminates aminopeptidase-mediated degradation. These modifications extend the plasma elimination half-life from approximately 3 to 4 minutes (oxytocin) to approximately 40 to 85 minutes (carbetocin), producing sustained uterotonic activity from a single 100 microgram intravenous or intramuscular injection [1, 2]. Carbetocin acts as a selective agonist at the oxytocin receptor (OXTR), a class A G protein-coupled receptor expressed on myometrial smooth muscle, myoepithelial cells of the mammary gland, and neuronal populations in the hypothalamus, amygdala, and brainstem. Molecular pharmacology studies have characterized carbetocin as a functionally selective (biased) Gq agonist: it activates the Gq/phospholipase C/inositol trisphosphate signaling cascade with partial agonist efficacy while inducing receptor internalization through a beta-arrestin-independent pathway that prevents receptor recycling to the plasma membrane [3]. This functional selectivity profile distinguishes carbetocin from native oxytocin (which recruits both Gq and beta-arrestin pathways) and from vasopressin V1a/V1b receptors at which carbetocin shows negligible agonist activity. The compound was first approved in 1997 (Duratocin, Pabal; Ferring Pharmaceuticals) for prevention of uterine atony following cesarean delivery and is now registered in more than 80 countries. The World Health Organization CHAMPION trial (Widmer et al. 2018), a 29,645-patient multinational randomized noninferiority study, demonstrated that a heat-stable formulation of carbetocin (100 microgram intramuscular) was noninferior to oxytocin (10 IU intramuscular) for prevention of postpartum hemorrhage after vaginal birth, establishing the compound as a viable alternative in settings where cold-chain storage is unavailable [4]. A second clinical development program, advanced by Acadia Pharmaceuticals, has evaluated intranasal carbetocin (3.2 to 9.6 mg three times daily) for the treatment of hyperphagia, anxiousness, and distress behaviors in Prader-Willi syndrome (PWS); the CARE-PWS Phase 3 trial (Kimonis et al. 2023) reported clinically meaningful improvements in hyperphagia at the 3.2 mg dose in 130 participants aged 7 to 18 years [5, 6]. Pharmacokinetics after intravenous administration show biphasic elimination with a terminal half-life of approximately 33 minutes; intramuscular administration produces a terminal half-life of approximately 55 minutes with bioavailability exceeding 80 percent [7]. The compound is well tolerated at registered doses; principal adverse events are nausea, vomiting, abdominal pain, flushing, headache, and transient hypotension, with a safety profile comparable to or more favorable than standard-dose oxytocin in pooled meta-analytic data [8, 9]. This monograph reviews the chemistry, synthesis, and structural modifications of carbetocin; the biased receptor pharmacology at the oxytocin receptor; comprehensive human pharmacokinetics; preclinical uterotonic and neurobehavioral pharmacology; the clinical evidence base across postpartum hemorrhage prevention and Prader-Willi syndrome indications; sourcing and quality verification considerations for research applications; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five alternative uterotonics and oxytocin-system compounds against carbetocin on five competency standards.